50–200 µg/day. It is pharmacologically active: use with caution.
May improve cognition in Alzheimer's; mostly Chinese studies, of uneven quality.
View the study (meta-analysis) →⏱ 3 min read
Huperzine A is an alkaloid isolated in the 1980s from the Chinese club moss Huperzia serrata, a plant used for centuries in traditional Chinese medicine for inflammation and memory disorders; its distinctive pharmacological feature is that it is a potent, reversible inhibitor of acetylcholinesterase, the enzyme that breaks down acetylcholine in the synaptic cleft, a property that places it in the same pharmacological family as the drugs used for mild to moderate Alzheimer's disease (donepezil, rivastigmine, galantamine) but with a natural profile, and it is marketed as a supplement in many countries.
Unlike pharmacological acetylcholinesterase inhibitors, which have significant cholinergic adverse effects (nausea, diarrhea, cramps, bradycardia) and require careful dose adjustment, huperzine A has greater selectivity for brain acetylcholinesterase over peripheral acetylcholinesterase, which translates into a more favorable tolerability profile at the doses used as a supplement, although very high doses can produce the same picture of cholinergic toxicity.
Several Chinese trials have shown significant improvements in cognition and activities of daily living in people with mild to moderate Alzheimer's disease at doses of 200-400 micrograms of huperzine A daily for 12-24 weeks, with effects comparable to those of first-generation pharmacological acetylcholinesterase inhibitors but with better gastrointestinal tolerability; Chinese meta-analyses consider huperzine A a reasonable alternative in patients who do not tolerate standard pharmacological anticholinesterase drugs.
Western data are scarcer and more heterogeneous: an American NIH-funded trial found no significant efficacy with 200 µg twice a day for 16 weeks in mild to moderate Alzheimer's disease, which has dampened enthusiasm for its clinical use outside China; these discrepancies could be due to differences in the quality and standardization of the products used or in the characteristics of the patients included.
In healthy young and middle-aged adults, several small studies have shown acute improvements in working memory, processing speed, and sustained attention with low doses of huperzine A (50-200 µg/day) over several weeks; these effects are modest but consistent and have popularized its use in cognitive optimization circles as part of nootropic "stacks" combined with racetams or choline.
Continued use at high doses in healthy people has not been well studied over the long term and raises theoretical concerns: sustained acetylcholinesterase inhibition may downregulate cholinergic receptors through desensitization, which could paradoxically worsen cognition in the long run; for this reason, many nootropic protocols recommend cycles of use (4-8 weeks with similar breaks) rather than indefinite continuous use.
The doses studied range from 50 to 400 micrograms daily (very small doses compared with most supplements), divided into one or two doses with or without food; products standardized to 1 percent purity (common in cognitive supplements) have the most clinical support; it is advisable to start with the lowest dose and increase gradually only if necessary.
Generally well tolerated at standard doses; the most frequent adverse effects are the typical cholinergic ones: nausea, dizziness, drowsiness, muscle cramps, sweating, and occasionally bradycardia (slow heartbeat); people with cardiovascular disease (especially bradyarrhythmias or AV block), asthma, peptic ulcer, hyperthyroidism, or seizures should avoid it; those taking pharmacological acetylcholinesterase inhibitors should not combine it with them because of the risk of additive cholinergic toxicity; it is best avoided during pregnancy and breastfeeding and in children because of limited data.
Information, not medical advice. Scientific evidence reflects the quality of the studies.